-

Dexcom Canada Achieves Great Place to Work® Certification for Second Consecutive Year

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (rtCGM), is proud to announce that for the second consecutive year, it has been certified as a Great Place to Work® in Canada for 2023-24. Awarded by Great Place to Work Institute®, the global authority on workplace culture, this certification is based on direct feedback from employees about their workplace experience, and the sentiment of pride they feel in representing Dexcom.

“Being recognized as a Great Place to Work in Canada for the second year in a row is a great achievement,” says André Côté, Vice President, General Manager at Dexcom Canada. “Dexcom has always been a purpose-driven company and it’s clear that our employees share that passion for the work that we do, in helping to empower people with diabetes to take control of their health. Many of our staff are personally affected by diabetes or have family members with diabetes, so their work at Dexcom is more than just a job. This certification would not be possible without their heart and dedication to their work and our mission as a company.”

Through the Great Place to Work® survey, Dexcom Canada employees awarded the organization high marks in areas such as supporting work-life balance and providing a psychologically and emotionally healthy place to work. The survey also revealed that Dexcom staff take pride in representing a company that helps those living with diabetes live a healthy, full life.

“We owe our success as a company to our team, for their ongoing efforts in creating and maintaining a positive environment, living our values, and showing up every day in a spirit of service. While we are honoured to be named a Great Place to Work® in Canada for the second time, we are always working to make our company a place where everyone feels like they can be themselves, which is also critical to making a meaningful impact in our community,” says Iris Nikolic, HR Business Partner.

Dexcom Canada continues to expand its presence across Canada and bring life-changing diabetes management technology to more Canadians. Visit Dexcom’s Careers page to learn more about available opportunities to join our growing team.

About Dexcom, Inc.

Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California in the United States, and with operations in Canada, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

About Great Place to Work®

Great Place to Work is the global authority on high-trust, high-performance workplace cultures. Through proprietary assessment tools, advisory services, and certification programs, Great Place to Work recognizes Canada’s Best Workplaces in a series of national lists including those published by The Globe & Mail (Canada) and Fortune magazine (USA). Great Place to Work provides the benchmarks, framework, and expertise needed to create, sustain, and recognize outstanding workplace cultures. Visit us at www.greatplacetowork.ca or find us on Twitter at @GPTW_Canada.

Contacts

Laura Andrejicka, 519.560.7860
Veritas Communications
andrejicka@veritasinc.com

Dexcom, Inc.

NASDAQ:DXCM

Release Versions

Contacts

Laura Andrejicka, 519.560.7860
Veritas Communications
andrejicka@veritasinc.com

More News From Dexcom, Inc.

Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program

SAN DIEGO--(BUSINESS WIRE)--Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence. Participation in the TEMPO pilot will allow Dexcom...

Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) for people 18 years and older living with diabetes. Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real‑time glucose readings for an industry‑leading 15.5 days5. Building on the performance of Dexcom CGM whi...

Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will...
Back to Newsroom